ATLCAR.CD30.CCR4 cells / UNC Lineberger Comprehensive Cancer Center - LARVOL DELTA

LCCC 1606-ATL: Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL (clinicaltrials.gov) - P1 | N=43 | Active, not recruiting | Sponsor: UNC Lineberger Comprehensive Cancer Center | Recruiting ➔ Active, not recruiting | Trial completion date: Sep 2041 ➔ Nov 2039 | Trial primary completion date: Sep 2026 ➔ Dec 2025

Enrollment closed • Trial completion date • Trial primary completion date • B Cell Lymphoma • Classical Hodgkin Lymphoma • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Mycosis Fungoides • Non-Hodgkin’s Lymphoma • Oncology • Sezary Syndrome • Skin Cancer • T Cell Non-Hodgkin Lymphoma • CCR4 • TNFRSF8

ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells (clinicaltrials.gov) - P1/2 | N=31 | Recruiting | Sponsor: UNC Lineberger Comprehensive Cancer Center | Not yet recruiting ➔ Recruiting

Enrollment open • IO biomarker • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells (clinicaltrials.gov) - P1/2 | N=31 | Not yet recruiting | Sponsor: UNC Lineberger Comprehensive Cancer Center

IO biomarker • New P1/2 trial • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

CD30-Directed CAR-T Cells Co-Expressing CCR4 in Relapsed/Refractory Hodgkin Lymphoma and CD30+ Cutaneous T Cell Lymphoma (TCT-ASTCT-CIBMTR 2022) - "Pts are lymphodepleted with 3 days of bendamustine 70 mg/m 2 and fludarabine 30 mg/m 2...All pts had prior brentuximab vedotin and 11 pts had prior checkpoint inhibitors... CCR4.CD30.CAR-Ts are safe with promising efficacy even at the lowest DL in pts with r/r HL, suggesting that early tumor homing may improve antitumor activity. Our data serve as a proof of concept for future modifications of CAR-T cells to improve localization to tumor sites."

CAR T-Cell Therapy • IO biomarker • Bone Marrow Transplantation • Cutaneous T-cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Inflammation • Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma • Transplantation • CCR4 • TNFRSF8

CD30-Directed CAR-T Cells Co-Expressing CCR4 in Relapsed/Refractory Hodgkin Lymphoma and CD30+ Cutaneous T Cell Lymphoma (ASH 2021) - P1 | "All patients receive lymphodepletion with 3 days of bendamustine 70 mg/m 2 and fludarabine 30 mg/m 2...All patients had received prior brentuximab vedotin...Two patients had grade 2 cytokine release syndrome (CRS) which resolved with tocilizumab, and 1 had self-limiting grade 1 CRS...Interestingly, responses are already seen at the lowest dose level, suggesting that early tumor homing driven by CCR4 may allow more fitted cells to better exploit their antitumor potential. Our data serve as a proof of concept for future modifications of CAR-T cells to improve their localization to disease sites."

CAR T-Cell Therapy • IO biomarker • Bone Marrow Transplantation • Cutaneous T-cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Inflammation • Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma • Transplantation • CCR4 • TNFRSF8